Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 23, 2019

MediWound reports positive top-line data from NexoBrid study

MediWound has reported positive top-line results from the Phase III DETECT study after the trial met its primary and secondary endpoints.

MediWound has reported positive top-line results from the Phase III DETECT study after the trial met its primary and secondary endpoints.

DETECT is a prospective, controlled, multi-centre trial of NexoBrid for the treatment of patients with deep partial thickness (DPT) and full thickness (FT) thermal burns.

The primary endpoint of the multi-national, assessor-blinded trial was the complete removal of eschar, measured by comparing all randomised patients in the NexoBrid arm with the patients in the Gel Vehicle control arm.

Results showed that patients who received NexoBrid achieved a significantly higher incidence (93.3%) of complete eschar removal compared with patients treated with gel vehicle (4%).

“These significant results clearly confirm its ability to remove the eschar earlier while significantly reducing patients’ surgical burden.”

Secondary endpoints of the trial comprised reduction in the need for surgical eschar removal, earlier eschar removal, and blood loss, which were assessed against the patients in the standard of care (SOC) control arm.

The trial also compared the time to complete wound closure and other standard safety measures with the SOC control arm.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

MediWound president and CEO Gal Cohen said: “We are thrilled to announce these robust positive results across all endpoints, which corroborate our previous positive EU Phase III clinical study results and clearly demonstrate the significant beneficial impact NexoBrid has on patients’ lives.

“Our innovative product, NexoBrid, represents a new paradigm in burn care management.

“These significant results clearly confirm its ability to remove the eschar earlier while significantly reducing patients’ surgical burden, two outcomes that are both clinically and pharmacoeconomically important.”

MediWound enrolled 175 patients who were randomised in 3:3:1 ratio to receive either NexoBrid, SOC, or the Gel Vehicle placebo as part of the DETECT study,

The trial included 12 and 24-month long-term safety follow-up period. It also included 44 burn centers.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU